Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer

被引:67
作者
Masuda, N
Matsui, K
Negoro, S
Takifuji, N
Takeda, K
Yana, T
Kobayashi, M
Hirashima, T
Kusunoki, Y
Ushijima, S
Kawase, I
Tada, T
Sawaguchi, H
Fukuoka, M
机构
[1] Osaka Prefectural Habikino Hosp, Dept Internal Med, Osaka 583, Japan
[2] Osaka Prefectural Habikino Hosp, Dept Radiol, Osaka 583, Japan
[3] Kinki Univ, Sch Med, Dept Internal Med 4, Osaka 589, Japan
[4] Osaka City Gen Hosp, Dept Resp Dis, Osaka, Japan
关键词
D O I
10.1200/JCO.1998.16.10.3329
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the response rate, survival and toxicity of irinotecan (CPT-11), a topoisomerase I inhibitor, combined with etoposide, a topoisomerase II inhibitor, in refractory or relapsed small-cell lung cancer (SCLC). Patients and Methods: Twenty-five patients with refractory or relapsed SCLC were entered onto the trial. All 25 patients had been pretreated with some form of cisplatin-based combination chemotherapy and had also received previous etoposide- or anthracycline-containing chemotherapy. The median time off chemotherapy was 6.7 months (range, 0.9 to 23.5). Patients were treated at 4-week intervals using CPT-11 (9 starting dose of 70 mg/m(2) intravenously on days 1, 8, and 15) plus etoposide (80 mg/m(2) intravenously on days 1 to 3), with a subsequent dose based on toxicity In addition, recombinant human granulocyte colony-stimulating factor (rhG-CSF; 2 mu g/kg/d) was given from day 4 to day 21, except on the days of CPT-I 1 administration. Results: All patients were assessable for toxicity and survival. Twenty-four patients were assessable for response. There were 14 partial responses (PRs) and three complete responses (CRs), for an overall response rate of 71% (95% confidence interval, 53% to 89%). The median response duration was 4.6 months. Median survival was 271 days. Major toxicities were myelosuppression (predominantly leukopenia) and diarrhea. Grade 3 to 4 neutropenia and thrombocytopenia occurred in 56% and 20% of patients, respectively. Grade 3 to 4 diarrhea was observed in 4%. There was one treatment-related death due to severe myelosuppression. Conclusion: A combination of CPT-11 and etopaside with rhG-CSF support is an active therapy against refractory or relapsed SCLC and deserves to be studied more extensively in a phase III trial. (C) 1998 by American Society of Clinical Oncology.
引用
收藏
页码:3329 / 3334
页数:6
相关论文
共 34 条
[31]   NONPRODUCTIVE REARRANGEMENT OF DNA TOPOISOMERASE-I AND TOPOISOMERASE-II GENES - CORRELATION WITH RESISTANCE TO TOPOISOMERASE INHIBITORS [J].
TAN, KB ;
MATTERN, MR ;
ENG, WK ;
MCCABE, FL ;
JOHNSON, RK .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (22) :1732-1735
[32]   MECHANISM OF ACTION OF ANTITUMOR DRUG ETOPOSIDE - A REVIEW [J].
VANMAANEN, JMS ;
RETEL, J ;
DEVRIES, J ;
PINEDO, HM .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1988, 80 (19) :1526-1533
[33]  
WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665
[34]  
World Health Organization, 1979, WHO OFFS PUBL